Semaglutide vs Tirzepatide: Which Holds Weight Better?

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the two heavyweight molecules of the GLP-1 era. The common question is which one is better. For weight loss on treatment, tirzepatide tends to win on average. But the question that decides whether your results last is different: which one holds weight better after you stop? The honest answer reframes the whole comparison.

How the two differ

Semaglutide is a GLP-1 receptor agonist: it activates one receptor, mimicking the gut hormone that signals fullness and slows gastric emptying. Tirzepatide is a dual agonist: it activates both the GLP-1 and the GIP receptor. That added GIP activity is the leading explanation for its larger average weight loss.

The trial numbers

In their respective phase 3 programs, the two molecules produced different magnitudes of weight loss, with tirzepatide generally higher at the top dose.

Individual response varies a lot, and so does tolerance. Some people do better, or feel better, on one than the other. Which molecule is appropriate for you is a clinical decision, not a leaderboard.

Which holds weight after you stop?

Here is the counterintuitive part. Larger loss on treatment can mean a larger rebound at cessation, because there is simply more weight that physiology will defend. Both molecules show substantial regain after stopping in withdrawal studies, driven by the same appetite-hormone rebound.

In other words, the off-ramp physiology is the same regardless of which you used. If anything, a bigger on-treatment loss calls for a more deliberate maintenance plan, not a more relaxed one.

What actually decides the outcome

The molecule sets how much you lose. Your habits set how much you keep. The evidence is consistent: protecting muscle with protein and resistance training, defending sleep, and tracking early after stopping are what convert a large loss into a lasting one.

• If you lost more, plan a more structured off-ramp, not a looser one.
• Build the pillars before you stop, while the drug is still helping.
• Track early, in the first weeks, when the rebound is steepest.

For a deeper side-by-side of the two molecules, see the full comparison. For keeping the loss, start with the maintenance guide.